





AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PG4734							
Applicant(s): BIGGADIKE, et. al.											
Serial No. 10/066,951	Filing Date 02/04/2002	Examiner BADIO		Group Art Unit 1616							
Invention: FORMULATION CONTAINING ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES											
<u>TO THE COMMISSIONER FOR PATENTS:</u>											
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.											
CLAIMS AS AMENDED											
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE						
TOTAL CLAIMS	18 -	20 =	0 x	\$18.00	\$0.00						
INDEP. CLAIMS	1 -	3 =	0 x	\$84.00	\$0.00						
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00						
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.											
 _____ Signature			Dated: 11-11-2003								
James P. Riek Registration No.: 39,009 Telephone: 919-483-8022 Customer No.: 23347			<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">I certify that this document and fee is being deposited on 11/11/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</td> </tr> <tr> <td colspan="2" style="text-align: center;">  Signature of Person Mailing Correspondence </td> </tr> <tr> <td colspan="2" style="text-align: center;"> Ban Younan Typed or Printed Name of Person Mailing Correspondence </td> </tr> </table>			I certify that this document and fee is being deposited on 11/11/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		 Signature of Person Mailing Correspondence		Ban Younan Typed or Printed Name of Person Mailing Correspondence	
I certify that this document and fee is being deposited on 11/11/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.											
 Signature of Person Mailing Correspondence											
Ban Younan Typed or Printed Name of Person Mailing Correspondence											
CC:											

IN THE UNITED STATES PATENT OFFICE

Applicant : Biggadike, et al.
Application No. : 10/066,951
Filed : 2/4/2002
Title : Formulation Containing Anti-Inflammatory Androstane
Derivatives

Grp./A.U. : 1616
Examiner : BADIO, Barbara P.

Docket No. : PG4734

Commissioner of Patents
Washington DC 20231

Amendment B

The following Amendment B is in response to the Official Action of October
3, 2003.

RECEIVED
NOV 21 2003
TECH CENTER 1600/2900

NOV 17 11:30 AM
TECH CENTER 1600/2900